Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD
James F Donohue,1 Tara Rheault,2 Margot MacDonald-Berko,2 Thomas Bengtsson,3 Kathleen Rickard2 1Division of Pulmonary and Critical Care Medicine, University of North Carolina, School of Medicine, Chapel Hill, NC, USA; 2Verona Pharma plc, Raleigh, NC, USA; 3Stat Mind AB, Lund, SwedenCorrespondence: T...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-07-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/ensifentrine-as-a-novel-inhaled-treatment-for-patients-with-copd-peer-reviewed-fulltext-article-COPD |
| _version_ | 1797769128388329472 |
|---|---|
| author | Donohue JF Rheault T MacDonald-Berko M Bengtsson T Rickard K |
| author_facet | Donohue JF Rheault T MacDonald-Berko M Bengtsson T Rickard K |
| author_sort | Donohue JF |
| collection | DOAJ |
| description | James F Donohue,1 Tara Rheault,2 Margot MacDonald-Berko,2 Thomas Bengtsson,3 Kathleen Rickard2 1Division of Pulmonary and Critical Care Medicine, University of North Carolina, School of Medicine, Chapel Hill, NC, USA; 2Verona Pharma plc, Raleigh, NC, USA; 3Stat Mind AB, Lund, SwedenCorrespondence: Tara Rheault, Verona Pharma, 8045 Arco Corporate Drive, Suite 130, Raleigh, NC, 27617, USA, Tel +1 646-530-2126, Email tara.rheault@veronapharma.comAbstract: Ensifentrine is a novel, potent, and selective dual inhibitor of phosphodiesterase (PDE)3 and PDE4 designed for delivery by inhalation that combines effects on airway inflammation, bronchodilation and ciliary function in bronchial epithelia. In Phase 2 studies in subjects with COPD, ensifentrine demonstrated clinically meaningful bronchodilation and improvements in symptoms and health-related quality of life when administered alone or in combination with current standard of care therapies. Ensifentrine is currently in late-stage clinical development for the maintenance treatment of patients with COPD. This review summarizes non-clinical data as well as Phase 1 and Phase 2 efficacy and safety results of nebulized ensifentrine relevant to the maintenance treatment of patients with COPD.Keywords: RPL554, nebulized therapy, chronic obstructive pulmonary disease, clinical efficacy, drug development |
| first_indexed | 2024-03-12T21:04:26Z |
| format | Article |
| id | doaj.art-d8d6a35b756d40d38a776d2206503666 |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-03-12T21:04:26Z |
| publishDate | 2023-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-d8d6a35b756d40d38a776d22065036662023-07-30T19:00:26ZengDove Medical PressInternational Journal of COPD1178-20052023-07-01Volume 181611162285518Ensifentrine as a Novel, Inhaled Treatment for Patients with COPDDonohue JFRheault TMacDonald-Berko MBengtsson TRickard KJames F Donohue,1 Tara Rheault,2 Margot MacDonald-Berko,2 Thomas Bengtsson,3 Kathleen Rickard2 1Division of Pulmonary and Critical Care Medicine, University of North Carolina, School of Medicine, Chapel Hill, NC, USA; 2Verona Pharma plc, Raleigh, NC, USA; 3Stat Mind AB, Lund, SwedenCorrespondence: Tara Rheault, Verona Pharma, 8045 Arco Corporate Drive, Suite 130, Raleigh, NC, 27617, USA, Tel +1 646-530-2126, Email tara.rheault@veronapharma.comAbstract: Ensifentrine is a novel, potent, and selective dual inhibitor of phosphodiesterase (PDE)3 and PDE4 designed for delivery by inhalation that combines effects on airway inflammation, bronchodilation and ciliary function in bronchial epithelia. In Phase 2 studies in subjects with COPD, ensifentrine demonstrated clinically meaningful bronchodilation and improvements in symptoms and health-related quality of life when administered alone or in combination with current standard of care therapies. Ensifentrine is currently in late-stage clinical development for the maintenance treatment of patients with COPD. This review summarizes non-clinical data as well as Phase 1 and Phase 2 efficacy and safety results of nebulized ensifentrine relevant to the maintenance treatment of patients with COPD.Keywords: RPL554, nebulized therapy, chronic obstructive pulmonary disease, clinical efficacy, drug developmenthttps://www.dovepress.com/ensifentrine-as-a-novel-inhaled-treatment-for-patients-with-copd-peer-reviewed-fulltext-article-COPDrpl554nebulized therapychronic obstructive pulmonary diseaseclinical efficacydrug development |
| spellingShingle | Donohue JF Rheault T MacDonald-Berko M Bengtsson T Rickard K Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD International Journal of COPD rpl554 nebulized therapy chronic obstructive pulmonary disease clinical efficacy drug development |
| title | Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD |
| title_full | Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD |
| title_fullStr | Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD |
| title_full_unstemmed | Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD |
| title_short | Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD |
| title_sort | ensifentrine as a novel inhaled treatment for patients with copd |
| topic | rpl554 nebulized therapy chronic obstructive pulmonary disease clinical efficacy drug development |
| url | https://www.dovepress.com/ensifentrine-as-a-novel-inhaled-treatment-for-patients-with-copd-peer-reviewed-fulltext-article-COPD |
| work_keys_str_mv | AT donohuejf ensifentrineasanovelinhaledtreatmentforpatientswithcopd AT rheaultt ensifentrineasanovelinhaledtreatmentforpatientswithcopd AT macdonaldberkom ensifentrineasanovelinhaledtreatmentforpatientswithcopd AT bengtssont ensifentrineasanovelinhaledtreatmentforpatientswithcopd AT rickardk ensifentrineasanovelinhaledtreatmentforpatientswithcopd |